HEB - Hemispherx Biopharma, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD

Hemispherx Biopharma, Inc.

2117 SW Highway 484
Ocala, FL 34473
United States

Full Time Employees31

Key Executives

NameTitlePayExercisedYear Born
Mr. Thomas K. EquelsExec. Vice Chairman, CEO & Pres835.28kN/A1953
Mr. Peter W. Rodino III, J.D.Exec. Director of Gov.al Relations, Gen. Counsel & Sec.387.68kN/A1951
Mr. Adam PascaleConsultant291.97kN/A1948
Mr. Wayne S. SpringateSr. VP of OperationsN/AN/A1971
Ms. Ellen LintalChief Accounting OfficerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Hemispherx Biopharma, Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. The company was founded in 1966 and is headquartered in Ocala, Florida.

Corporate Governance

Hemispherx Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.